Clinical Trials Logo

Clinical Trial Summary

In most parts of the world, mRNA vaccines were used to provide protection to population against COVID 19. However, in some countries, including Pakistan, traditional viral vaccines named as Sinovac and Sinopharm were used for mass level immunization. Though these vaccines were approved by WHO, their efficacy had been questioned. Now after recommendation of booster doses, we aim to see the effect of mRNA vaccine as a booster dose after Sinovac and Sinopharm in terms of antibody response. (IgG RBD SARS CoV2)


Clinical Trial Description

In most parts of the world, mRNA vaccines were used to provide protection to population against COVID 19. However, in some countries, including Pakistan, traditional viral vaccines named as Sinovac and Sinopharm were used for mass level immunization. Though these vaccines were approved by WHO, their efficacy had been questioned. Now after recommendation of booster doses, we aim to see the effect of mRNA vaccine (BNT162b2, pfizer) as a booster dose after Sinovac and Sinopharm in terms of antibody response. (IgG RBD SARS CoV2). The antobody IgG RBD levels will be checked before the booster dose and then after 3 weeks of the booster. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05213455
Study type Observational [Patient Registry]
Source Lahore General Hospital
Contact
Status Active, not recruiting
Phase
Start date January 1, 2022
Completion date March 15, 2022

See also
  Status Clinical Trial Phase
Completed NCT05057910 - SARS-CoV-2 (Covid-19) RBD Antibody in My Duc Hospital Healthcare Workers
Recruiting NCT05028257 - Allergy and COVID-19 Vaccines Phase 3
Completed NCT04798677 - Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine N/A
Not yet recruiting NCT05546502 - Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children Phase 2/Phase 3
Not yet recruiting NCT05482295 - Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III) Phase 3
Active, not recruiting NCT05098600 - The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
Completed NCT03600428 - Safety of LAIV4 in Children With Asthma Phase 4
Completed NCT03400878 - Comparing Morbidity and Mortality Effects of Two Different Strains of BCG Phase 4
Recruiting NCT05116748 - COVID19 Vaccine in SOT Adult Recipients
Recruiting NCT05069714 - One or Two Week Methotrexate Discontinuation on Efficacy of Influenza Vaccination in Rheumatoid Arthritis. Phase 3
Completed NCT04576910 - Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China Phase 4
Not yet recruiting NCT05094635 - Immunogenicity Against SARS-CoV-2 in COVID-19 Close Contacts
Recruiting NCT05493917 - A Real-world Study to Evaluate the Safety and Immunogenicity of a Third-dose Booster After Two Doses of an Inactivated COVID-19 Vaccine
Completed NCT05154383 - Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) Versus Standard-Dose (QIV-SD), in Subjects 65 Years of Age and Older on Innate Immunity, Including Gene Expression Phase 4
Recruiting NCT05128721 - Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19) Phase 1
Not yet recruiting NCT05028322 - Evaluation of Intradermal Hepatitis B Vaccine After IMIQUIMOD's Application, in Cirrhotics Who Did Not Respond to the Usual Vaccine Regimen Phase 2
Active, not recruiting NCT05515081 - Antibody Response and Longevity Post SARS-CoV-2 Vaccine (SARS-AB) N/A
Recruiting NCT05359250 - Myocardial Injury and Dysfunction Associated With COVID-19 Vaccination
Recruiting NCT04883177 - Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101)
Completed NCT04922944 - Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients